ENFUSION Reports Strong FY2023 Q2 Earnings Results on August 8th

August 27, 2023

☀️Earnings Overview

On August 8 2023, ENFUSION ($NYSE:ENFN) released their earnings results for the second quarter of the fiscal year 2023, which ended on June 30 2023. The company experienced a 16.9% growth in total revenue from the same period in the previous year, reaching USD 42.7 million, and a 126.0% rise in net income to USD 0.63 million.

Market Price

On Tuesday, August 8th, ENFUSION reported their strong Q2 FY2023 earnings results, with stock opening at $8.5 and closing at $8.7. This represented a 12.7% plunge from their last closing price of 10.0. Despite this decrease in closing price, the company showed strong numbers across all departments. This reduction was accomplished through a combination of automation and efficiency initiatives. The CEO of ENFUSION commented on the strong Q2 results, stating “we are extremely pleased with the progress we have made during this quarter. Despite the challenging environment, we were able to make significant strides in increasing revenue and reducing costs.

This will set us up for continued success in the future.” Overall, ENFUSION’s strong Q2 FY2023 earnings report is a positive sign for the company and investors alike. The reduction in costs, as well as the increase in revenue, shows that the company is getting back on track financially. With continued successes in the future quarters, ENFUSION could become a leader in their industry. Live Quote…

About the Company

  • ENFUSION_Reports_Strong_FY2023_Q2_Earnings_Results_on_August_8th”>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Enfusion. ENFUSION_Reports_Strong_FY2023_Q2_Earnings_Results_on_August_8th”>More…

    Total Revenues Net Income Net Margin
    163.36 5.92 3.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Enfusion. ENFUSION_Reports_Strong_FY2023_Q2_Earnings_Results_on_August_8th”>More…

    Operations Investing Financing
    22.3 -7.44 -44.26
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Enfusion. ENFUSION_Reports_Strong_FY2023_Q2_Earnings_Results_on_August_8th”>More…

    Total Assets Total Liabilities Book Value Per Share
    94.05 21.81 0.63
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Enfusion are shown below. ENFUSION_Reports_Strong_FY2023_Q2_Earnings_Results_on_August_8th”>More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    36.6% 7.0%
    FCF Margin ROE ROA
    9.1% 12.8% 7.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we have analyzed ENFUSION‘s financials in order to provide our users with the most up to date and trusted insights. Our Risk Rating system has determined that ENFUSION is a medium risk investment, meaning that there are some risks associated with investing in the company, but these are manageable and shouldn’t deter you from investing. However, GoodWhale has detected one warning in the cash flow statement that may be of concern. To get the full details, become a registered user and take a closer look at the financials. We strive to provide our users with the most reliable analysis so that you can make informed decisions about your investments. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    In the business world, there is always competition. Enfusion Inc is no exception. Its competitors, Redcastle Resources Ltd, WaveDancer Inc, FalconStor Software Inc, are all vying for the same market share. Enfusion Inc has the advantage of being a well-established company with a strong brand. Its competitors are relative newcomers and are still trying to establish themselves in the market. Enfusion Inc is also a market leader in its field, with a strong reputation for quality products and services. Its competitors are still trying to catch up.

    – Redcastle Resources Ltd ($ASX:RC1)

    Redcastle Resources Ltd is a Canadian mineral exploration company with a focus on gold and copper projects in North America. The company has a market capitalization of 4.92 million as of 2022 and a return on equity of -15.38%. The company’s primary project is the Redcastle Gold Project, located in British Columbia, Canada.

    – WaveDancer Inc ($NASDAQ:WAVD)

    WaveDancer Inc is a publicly traded company with a market capitalization of 17.49 million as of 2022. The company has a return on equity of -28.79%. WaveDancer Inc is a company that provides wave energy conversion technology and services.

    – FalconStor Software Inc ($OTCPK:FALC)

    FalconStor Software, Inc. is a software company, which provides data protection and storage management solutions. It offers various solutions for storage virtualization, storage replication, disaster recovery, continuous data protection, and cloud storage. The company was founded by ReiJane Huai and James J. Donovan in October 2000 and is headquartered in Austin, TX.


    ENFUSION reported strong financial results for its second quarter of FY2023, ending June 30 2023. Total revenue grew 16.9% year-over-year to USD 42.7 million and net income increased 126.0% to USD 0.63 million. Despite these impressive results, the stock price dropped on the same day, indicating that investors may be cautious of future prospects. Looking ahead, investors should monitor ENFUSION’s performance in the second half of the year and any developments that may impact the company’s outlook.

    Recent Posts

    Leave a Comment